骨髓抽吸浓缩液联合适当载体有效促进兔慢性肩袖撕裂模型骨-肌腱界面愈合
该研究在兔慢性肩袖撕裂模型中评估骨髓抽吸浓缩液(BMAC)联合不同载体对骨-肌腱界面(BTI)愈合的影响。体外实验显示BMAC联合去端胶原(ATC)的多向分化能力强于单用BMAC或BMAC联合聚脱氧核糖核苷酸(PDRN)(P < .001)。体内实验将64只兔随机分为4组,结果显示BMAC-ATC组在4周和12周时促进BTI愈合的效果最佳,而无适当载体的BMAC不能增强BTI愈合。
要点
- 体外实验中BMAC联合ATC的多向分化能力显著强于单用BMAC或BMAC联合PDRN(P < .001)。
- 体内实验中BMAC-ATC组在4周时聚集蛋白聚糖、骨形态发生蛋白2和I型胶原α1表达水平最高(均P < .001)。
- 12周时BMAC-ATC组胶原纤维连续性、密度和BTI成熟度及失效载荷均显著优于其他组(均P < .001)。
核心结论
- 局部应用无适当载体的BMAC不能增强BTI愈合,而BMAC联合两种不同载体均有效加速BTI愈合,尤其在ATC环境下效果更佳。
- 作者认为BMAC与ATC联合可能作为一种强有力的生物制剂,在兔慢性肩袖撕裂模型中促进肩袖修复术后愈合。
研究设计与样本
- 控制性实验室研究,体外评估BMAC联合不同载体(PDRN和ATC)的生长因子量和分化潜能。
- 体内实验将64只兔随机分为4组:对照组(生理盐水)、BMAC组(BMAC加生理盐水)、BMAC-PDRN组(BMAC联合PDRN)、BMAC-ATC组(BMAC联合ATC),每组n = 16。
- 修复术后4周和12周进行基因与组织学分析,术后12周进行生物力学评估。
主要发现
- 体外实验中,BMAC联合ATC的多向分化程度显著强于单用BMAC或BMAC联合PDRN(P < .001)。
- 体内实验中,术后4周BMAC-ATC组的聚集蛋白聚糖、骨形态发生蛋白2和I型胶原α1表达水平在所有组中最高(均P < .001)。
- 术后12周BMAC-ATC组与其他组相比显示胶原纤维连续性、更致密的胶原纤维和更成熟的BTI(均P < .001)。
- 术后12周BMAC-ATC组的失效载荷显著高于其余各组(均P < .001)。
临床怎么用
- 作者认为BMAC与ATC联合可能协同促进肩袖肌腱愈合。
- 原文指出局部应用无适当载体的BMAC不能增强BTI愈合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of bone marrow aspirate concentrate (BMAC) in promoting bone-tendon interface (BTI) healing without any carriers remains a subject of debate. PURPOSE: To evaluate BMAC effects with different carriers on tendon regeneration in a rabbit model of chronic rotator cuff tear. STUDY DESIGN: Controlled laboratory study. METHODS: In vitro, the amount of growth factor and the differentiation potential of BMAC with different carriers (polydeoxyribonucleotide [PDRN] and atelocollagen [ATC]) were assessed. In vivo, 64 rabbits were randomly allocated into 4 groups. Different materials were injected into the repair site according to the allocated group: control, saline; BMAC, BMAC and saline; BMAC-PDRN, BMAC with PDRN; BMAC-ATC, BMAC with ATC (n = 16 in each). Genetic and histologic analyses were conducted at 4 and 12 weeks after repair, while biomechanical evaluations were performed at 12 weeks after repair. RESULTS: In vitro, the degree of multilineage differentiation was much stronger using BMAC with ATC as compared with administration of BMAC alone or BMAC with PDRN (P < .001). In vivo, the BMAC-ATC group had the highest levels of aggrecan expression, bone morphogenetic protein 2, and collagen type I alpha 1 among all groups (all P < .001) at 4 weeks after repair. Furthermore, the BMAC-ATC group showed collagen fiber continuity, denser collagen fibers, and more mature BTI as compared with the other groups (all P < .001) at 12 weeks after repair. Concurrently, the BMAC-ATC group also demonstrated significantly higher load-to-failure versus the remaining groups (all P < .001) at 12 weeks after repair. CONCLUSION: Local application of BMAC without appropriate carriers could not enhance BTI healing. However, BMAC with 2 different carriers effectively accelerated BTI healing, particularly in the ATC environment. Therefore, the combination of BMAC and ATC may act as a powerful biological agent to promote healing after rotator cuff repair in a chronic rotator cuff tear model using rabbits. CLINICAL RELEVANCE: Local application of BMAC without appropriate carriers could not enhance BTI healing. However, the combination of BMAC and ATC may synergistically promote rotator cuff tendon healing.
引用
- Han SC, Han J, Kim YK, et al. Bone Marrow Aspirate Concentrate Combined With an Appropriate Carrier Effectively Promotes Bone-Tendon Interface Healing in a Rabbit Model of Chronic Rotator Cuff Tear. Am J Sports Med. 2025. PMID: 39876035. doi:10.1177/03635465241313124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。